

# DEPARTMENT OF IMMUNOLOGY



# **ABOUT US**

We are dedicated to research & development of cellular therapy for cancer and autoimmune diseases. Recently we have developed a dendritic cell-based cancer vaccine. Clinical evaluation and further development of the vaccine was transferred to biotech company. This vaccine and its modifications constitute a foundation for the contemporary development of a technology for ex vivo production of antigen-specific T-lymphocytes. The goal of our work is to produce antigen-specific T-lymphocytes that would allow their use for cancer therapy and therapy of autoimmune diseases. Our study is primarily focused on prostate cancer and type 1 diabetes.

### KONTAKTY

Department of Immunology V Úvalu 84 150 06 Prague 5

# **WE OFFER**


We offer imaging flow cytometer Image Stream X Mark II that combines flow cytometry with microscopy imaging. This combination takes advantage of the flow cytometry in speed, robustness and sensitivity, and advantage of microscopy in morphology analysis and spatial distribution of the acquired signal from the analyzed cells.

The instrument allows studies on, namely, cell signaling, internalization&phagocytosis, apoptosis, intracellular co-localization, morphology and cell-cell interactions; and all this with a statistical robustness. Due to the visualization it is possible to eliminate artifacts like non-cell objects or antibody aggregates.

Prof. MUDr. Jiřina Bartůňková, DrSc.

(head of department) tel.: +420 224435960 fax: +420 224435962

e-mail: jirina.bartunkova@lfmotol.cuni.cz





# www.lf2.cuni.cz/en

# CONTACT

Prof. MUDr. Anna Šedivá, DSc.

(head physician)

tel.: +420 224435960 fax: +420 224435962

email: anna.sediva@lfmotol.cuni.cz

RNDr. Daniel Smrž, Ph.D. (principle investigator)

tel.: +420 22443 5968 Fax: +420 22443 5962

email: daniel.smrz@lfmotol.cuni.cz

## SELECTED PUBLICATIONS:

Podrazil, M., Horvath, R., Becht, E., Rozkova, D., Bilkova, P., Sochorova, K., Hromadkova, H., Kayserova, J., Vavrova, K., Lastovicka, J., Vrabcova, P., Kubackova, K., Gasova, Z., Jarolim, L., Babjuk, M., Spisek, R., Bartunkova, J., and Fucikova, J.

(2015) Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

Oncotarget 6, 18192-1820

Dáňová, K., Klapetková, A., Kayserová, J., Šedivá, A., Špíšek, R., and Jelínková, L. P.

(2015) NF-kappaB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment.

Oncotarget 6, 14123-14138

Fucikova, J., Moserova, I., Truxova, I., Hermanova, I., Vancurova, I., Partlova, S., Fialova, A., Sojka, L., Cartron, P. F., Houska, M., Rob, L., Bartunkova, J., and Spisek, R.

(2014) High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer 135, 1165-1177

Kayserová, J., Včeláková, J., Stechova, K., Dudková, E., Hromádková, H., Sumnik, Z., Kolousková, S., Špíšek, R., and Šedivá, A.

(2014) Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients.

Clinical immunology 153, 49-55

Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., and Špíšek, R. **(2011) Human tumor cells killed by anthracyclines induce a tumor-specific immune response.** Cancer Res 71, 4821-4833

